ASH 2022 | The need for disease-modifying therapies in MPNs
Andrew Kuykendall, MD, Moffitt Cancer Center, Tampa, FL, discusses the need for disease-modifying therapies in myeloproliferative neoplasms (MPNs), acknowledging that few drugs are able to induce complete remission (CR) in patients. Dr Kuykendall highlights the need for mutation-specific inhibitors of JAK2, as well as earlier clinical intervention in myelofibrosis (MF). This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Protagonist: Other: Research Support; Imago Biosciences: Consultancy, Honoraria, Speakers Bureau; Incyte: Consultancy, Honoraria, Speakers Bureau; Blueprint Medicines Corporation: Consultancy, Honoraria, Research Funding, Speakers Bureau; Novartis: Consultancy, Honoraria, Speakers Bureau; Abbvie: Consultancy, Honoraria, Speakers Bureau; GSK – Sierra Oncology: Consultancy, Honoraria, Other: Research Support, Speakers Bureau; Prelude Pharmaceuticals: Other: Research Support; BMS: Consultancy, Honoraria, Other: Research Support, Speakers Bureau; Morphosys: Other: Research Support; Pharmaessentia: Consultancy, Honoraria, Speakers Bureau; CTI Biopharma: Consultancy, Honoraria, Speakers Bureau.
